(object) array( 'id' => '2432466', 'url' => 'FR/bath_salts', 'image' => 'Bath Salts.jpg;', 'title' => 'Sels de bain', 'tags' => array ( 0 => 'Sels de bain', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Sels de bain', 'source_id' => 1303057, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084118', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Une poudre également connue sous le nom de "Ivory Wave", "Vanilla Sky" et "Blue Magic", qui est légalement disponible dans la plupart des pays, et peut avoir des effets hallucinogènes et même mortels. Ces sels sont souvent associés à tort aux sels de bain normaux inoffensifs, qui peuvent être ajoutés aux bains pour imiter les effets d\'une source thermale. De nombreux États américains envisagent l\'interdiction de la drogue, qui contient de la méphédrone ou une autre drogue appelée MDPV.', 'usage_comment' => '', 'glossary' => '', 'width' => 600, 'height' => 448, '_version_' => 1507294573050724352, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'bath salts', 'Definition' => 'A powder substance also known as Ivory Wave, Vanilla Sky and Blue Magic, which is legally available in most countries, and can have hallucinogenic and even fatal effects. It is often mistakenly associated with harmless, normal bath salts, which can be added to baths to mimic the effects of a hot spring. Many American states are considering banning the drug, which contains mephedrone or another drug called MDPV.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Sample Image' => 'Bath Salts.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Special Term' => 'TIN', 'Other Reference' => 'TIN', 'Creation User' => 'Robert Derbyshire', 'Creation Date' => '2011/5/23', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'bath_salts', )

(object) array( 'id' => '6229090', 'url' => 'FR/comparison_group_₂', 'image' => '', 'title' => 'Groupe de comparaison', 'tags' => array ( 0 => 'Groupe de comparaison', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Groupe de comparaison', 'source_id' => 4011326, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104707', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un groupe de participants à une étude clinique qui est utilisé pour synthétiser les données recueillies lors de l\'étude. Ce groupe peut être identique ou différent d\'un bras de l\'étude.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431488, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'A grouping of participants in a clinical study that is used in summarizing the data collected during the study. This grouping may be the same as or different from a study arm.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Synonym' => 'reporting_group', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'comparison group', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'comparison_group_₂', )

(object) array( 'id' => '6877605', 'url' => 'FR/Angiotensin_II_Receptor_Blockers_(ARBs)', 'image' => '', 'title' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'tags' => array ( 0 => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Antagonistes des récepteurs de l\'angiotensine II (ARA II)', 'source_id' => 1038764, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084107', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Médicaments qui bloquent l\'action de l\'angiotensine II en l\'empêchant de se lier à des récepteurs de l\'angiotensine II sur les vaisseaux sanguins.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573051772930, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Angiotensin II Receptor Blockers (ARBs)', 'Definition' => 'Medications that block the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on blood vessels.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'CCTRADUCTION', 'Creation Date' => '2011/4/12', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Angiotensin_II_Receptor_Blockers_(ARBs)', )

(object) array( 'id' => '6229091', 'url' => 'FR/study_design', 'image' => '', 'title' => 'Plan d\'étude', 'tags' => array ( 0 => 'Plan d\'étude', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Plan d\'étude', 'source_id' => 4011443, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104709', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les méthodes d\'investigation utilisées dans l\'étude clinique. Pour les études interventionnelles, celles-ci incluent un objectif principal, un modèle d\'intervention, en insu ou en aveugle, et une affectation.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081754431489, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The investigative methods used in the clinical study. For interventional studies, these include primary purpose, intervention model , masking or blinding, and allocation.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'study design', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'study_design', )

(object) array( 'id' => '2315639', 'url' => 'FR/spirulina_₁', 'image' => 'espirulina-3.jpg', 'title' => 'Spiruline', 'tags' => array ( 0 => 'Spiruline', 1 => 'Pharmaceutical', 2 => 'Healthcare supplement', 3 => '', ), 'term' => 'Spiruline', 'source_id' => 1658962, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Healthcare supplement', ), 'lastedit' => '20150721112809', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'La spiruline est une bactérie bleu-vert du groupe des cyanobactéries ayant une forte valeur nutritionnelle : elle contient des protéines et de la vitamine B12. Les compléments alimentaires sont composés de deux espèces de spiruline : Arthrospira platensis et Arthrospira maxima. Elle est devenue populaire en tant que complément alimentaire à la fin du XXe siècle.', 'usage_comment' => '', 'glossary' => '', 'width' => 250, 'height' => 280, '_version_' => 1507305079939530752, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'spirulina', 'Definition' => 'Spirulina is a green-blue bacterium of the Cyanobacteria group of a high nutritional value: it contains proteins and B12 vitamin. The nutritional supplements are made of two species of spirulina: Arthrospira platensis and Arthrospira maxima. It became popular as a nutritional supplement at the end of the XX century.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Healthcare supplement', 'Creation User' => 'esb', 'Creation Date' => '2011/10/6', 'Sample Image' => 'espirulina-3.jpg', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'spirulina_₁', )

(object) array( 'id' => '3897820', 'url' => 'FR/variable-interval_₁', 'image' => '', 'title' => 'Intervalle variable', 'tags' => array ( 0 => 'Intervalle variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Intervalle variable', 'source_id' => 3744241, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105901', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un renforçateur dépend de la première réponse après un intervalle de temps variable depuis la dernière opportunité pour un renforcement.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851727282176, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'A reinforcer is contingent on the first response after a variable interval of time since the last opportunity for reinforcement.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable-interval', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable-interval_₁', )

(object) array( 'id' => '10479592', 'url' => 'FR/amino_acids_₁₂', 'image' => '', 'title' => 'Acides aminés', 'tags' => array ( 0 => 'Acides aminés', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Acides aminés', 'source_id' => 5094749, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083421', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les blocs de construction des protéines qui composent collagène et d\'élastine-substances qui donnent à la peau son soutien structurel. Le vieillissement et une combinaison de facteurs externes (dont la lumière UV et les toxines environnementales) réduisent le niveau des acides aminés dans le corps ; les crèmes contenant des acides aminés peuvent aider à les restaurer.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984707, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'The building blocks of the proteins that make up collagen and elastin—substances that give the skin its structural support. Aging and a combination of external factors (including UV light and environmental toxins) reduce the level of amino acids in the body; creams containing amino acids may help restore them.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/16', 'Term' => 'amino acids', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'amino_acids_₁₂', )

(object) array( 'id' => '3951142', 'url' => 'FR/Yawning-No-More', 'image' => 'yawning.jpg; bush yawning.jpg;', 'title' => 'Yawning-No-More', 'tags' => array ( 0 => 'Yawning-No-More', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Yawning-No-More', 'source_id' => 639288, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084108', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un nouveau médicament de relaxation musculaire qui stoppe les bâillements pendant un certain nombre d\'heures. Le bâillement est une réaction allergique du corps à cause de la fatigue, du manque de stimulation, ou de l\'ennui. Yawning-No-More détend les muscles qui induisent le bâillement ainsi la personne peut éviter de bâiller jusqu\'à cinq heures. Le bâillement peut être gênant lors de rassemblements sociaux ou des réunions d\'affaires car il peut montrer un manque d\'intérêt ou d\'énergie. Ce nouveau médicament promet de changer sensiblement la façon dont la société voit le bâillement.', 'usage_comment' => '', 'glossary' => '', 'width' => 503, 'height' => 340, '_version_' => 1507294573051772928, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Yawning-No-More', 'Definition' => 'A new muscle relaxation drug that stops yawning for a number of hours. Yawing is an allergic reaction of the body due to tiredness, lack of stimulation, or boredom. Yawning-No-More relaxes the muscles that induce yawning so the person can be spared of yawning for up to five hours. Yawning can be embarrassing during social gatherings or business meetings as it may show a lack of interests or energy. This new drug promises to substantially change the way society views yawning.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'yawning.jpg; bush yawning.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'BruceLH', 'Creation Date' => '2011/1/23', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Yawning-No-More', )

(object) array( 'id' => '6227764', 'url' => 'FR/sponsor_investigator', 'image' => '', 'title' => 'Sponsor-investigateur', 'tags' => array ( 0 => 'Sponsor-investigateur', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Sponsor-investigateur', 'source_id' => 4010894, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105912', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'La personne qui initie et conduit l\'étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851745107968, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The person who both initiates and conducts the clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'sponsor investigator', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'sponsor_investigator', )

(object) array( 'id' => '6227397', 'url' => 'FR/exclusion_criteria_₁', 'image' => '', 'title' => 'Critères d\'exclusion', 'tags' => array ( 0 => 'Critères d\'exclusion', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critères d\'exclusion', 'source_id' => 4010892, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105910', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les facteurs ou les raisons qui empêchent une personne de participer à une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059394, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The factors or reasons that prevent a person from participating in a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'exclusion criteria', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'exclusion_criteria_₁', )